Precision Therapy: The NCI-Match Trial

Precision Therapy: The NCI-Match Trial

MUSC Health medical oncologist John M. Wrangle, M.D.,  discusses the National Cancer Institute trial, Molecular Analysis for Therapy Choice (NCIMATCH), which seeks to personalize treatment for patients with advanced cancer that has returned or worsened after standard systemic therapy. MUSC Hollings Cancer, an NCI-designated cancer center, is one of the sites for this study.

More at Progressnotes, MUSC’s Medical Magazine


November 16, 2016

Created by

The Medical University of South Carolina